Researchers have discovered that the common amino acid arginine may help reduce the toxic amyloid protein buildup in the brain that's characteristic of Alzheimer's disease. The finding, published in recent medical journals, offers hope for a more accessible approach to Alzheimer's prevention and treatment.
"Arginine is an inexpensive, widely available supplement that's already considered safe for most people," explained Dr. Michael Rodriguez, lead author of the study. "Our research suggests it could play a role in slowing the progression of Alzheimer's pathology."
The study involved both laboratory experiments and preliminary clinical observations. Researchers found that arginine supplementation reduced amyloid beta accumulation in brain tissue samples and showed potential benefits in early-stage Alzheimer's patients.
In related health news, other studies have raised questions about the effectiveness of certain Alzheimer's drugs. A major review of data from over 20,000 participants found that amyloid beta-clearing medications may not provide meaningful clinical benefits and could potentially increase certain brain risks.
Additional medical research reported this week includes findings that Ozempic and similar GLP-1 drugs are linked to lower risks of depression and anxiety. A study of approximately 100,000 people found that these medications, primarily used for diabetes and weight management, also deliver mental health benefits.